This company has been marked as potentially delisted and may not be actively trading. Vital Therapies (VTL) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock VTL vs. EPRX, NKTX, MGNX, ASMB, GLSI, HURA, THTX, CTNM, ATOS, and BHSTShould you be buying Vital Therapies stock or one of its competitors? The main competitors of Vital Therapies include Eupraxia Pharmaceuticals (EPRX), Nkarta (NKTX), MacroGenics (MGNX), Assembly Biosciences (ASMB), Greenwich LifeSciences (GLSI), TuHURA Biosciences (HURA), Theratechnologies (THTX), Contineum Therapeutics (CTNM), Atossa Therapeutics (ATOS), and BioHarvest Sciences (BHST). These companies are all part of the "medical" sector. Vital Therapies vs. Its Competitors Eupraxia Pharmaceuticals Nkarta MacroGenics Assembly Biosciences Greenwich LifeSciences TuHURA Biosciences Theratechnologies Contineum Therapeutics Atossa Therapeutics BioHarvest Sciences Vital Therapies (NASDAQ:VTL) and Eupraxia Pharmaceuticals (NASDAQ:EPRX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, community ranking, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation. Do analysts rate VTL or EPRX? Eupraxia Pharmaceuticals has a consensus target price of $10.50, indicating a potential upside of 172.02%. Given Eupraxia Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Eupraxia Pharmaceuticals is more favorable than Vital Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vital Therapies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Eupraxia Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Which has stronger valuation & earnings, VTL or EPRX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVital TherapiesN/AN/A-$41.47MN/AN/AEupraxia PharmaceuticalsN/AN/A-$28.22M-$0.76-5.08 Is VTL or EPRX more profitable? Eupraxia Pharmaceuticals' return on equity of -219.64% beat Vital Therapies' return on equity.Company Net Margins Return on Equity Return on Assets Vital TherapiesN/A -235.33% -182.35% Eupraxia Pharmaceuticals N/A -219.64%-96.00% Which has more volatility & risk, VTL or EPRX? Vital Therapies has a beta of 3.51, suggesting that its share price is 251% more volatile than the S&P 500. Comparatively, Eupraxia Pharmaceuticals has a beta of 0.65, suggesting that its share price is 35% less volatile than the S&P 500. Does the MarketBeat Community prefer VTL or EPRX? Vital Therapies received 365 more outperform votes than Eupraxia Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Eupraxia Pharmaceuticals an outperform vote while only 74.40% of users gave Vital Therapies an outperform vote. CompanyUnderperformOutperformVital TherapiesOutperform Votes36974.40% Underperform Votes12725.60% Eupraxia PharmaceuticalsOutperform Votes4100.00% Underperform VotesNo Votes Do institutionals and insiders hold more shares of VTL or EPRX? 15.5% of Vital Therapies shares are held by institutional investors. 33.9% of Vital Therapies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the media favor VTL or EPRX? In the previous week, Eupraxia Pharmaceuticals had 1 more articles in the media than Vital Therapies. MarketBeat recorded 1 mentions for Eupraxia Pharmaceuticals and 0 mentions for Vital Therapies. Eupraxia Pharmaceuticals' average media sentiment score of 1.87 beat Vital Therapies' score of 0.00 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Vital Therapies Neutral Eupraxia Pharmaceuticals Very Positive SummaryEupraxia Pharmaceuticals beats Vital Therapies on 10 of the 14 factors compared between the two stocks. Get Vital Therapies News Delivered to You Automatically Sign up to receive the latest news and ratings for VTL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VTL vs. The Competition Export to ExcelMetricVital TherapiesPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$34.10M$6.87B$5.57B$8.50BDividend YieldN/A2.53%5.28%4.16%P/E RatioN/A8.4326.6319.64Price / SalesN/A262.52407.99152.17Price / CashN/A65.8538.2534.64Price / Book2.786.536.964.60Net Income-$41.47M$143.25M$3.23B$248.06M Vital Therapies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VTLVital TherapiesN/A$0.80-4.6%N/A-31.4%$34.10MN/A0.0010EPRXEupraxia Pharmaceuticals1.9468 of 5 stars$3.92-0.5%$10.50+167.8%+39.9%$140.56MN/A-5.4529NKTXNkarta3.6295 of 5 stars$1.97+5.1%$14.67+646.4%-70.1%$139.43MN/A-1.05140Analyst ForecastMGNXMacroGenics3.7806 of 5 stars$2.04+24.2%$5.71+180.5%-67.5%$129.46M$152.43M-1.30430Options VolumeGap DownHigh Trading VolumeASMBAssembly Biosciences4.0301 of 5 stars$16.81+4.6%$33.00+96.3%+11.4%$128.40M$32.15M-2.70100Short Interest ↓Gap DownGLSIGreenwich LifeSciences2.2288 of 5 stars$9.52+0.7%$39.00+309.9%-38.0%$127.20MN/A-11.893Positive NewsHURATuHURA BiosciencesN/A$2.81-2.6%$12.67+351.6%N/A$122.48MN/A0.00N/ANews CoverageAnalyst DowngradeTHTXTheratechnologiesN/A$2.59-0.4%N/A+96.8%$119.09M$88.67M-25.90140Positive NewsCTNMContineum Therapeutics2.5548 of 5 stars$4.59+2.3%$22.50+390.7%-73.3%$118.62M$50M-2.3331ATOSAtossa Therapeutics1.4701 of 5 stars$0.90-1.1%$6.17+582.2%-32.5%$116.77MN/A-4.118BHSTBioHarvest SciencesN/A$6.98+0.3%$13.67+95.8%N/A$114.65M$27.70M-5.59N/A Related Companies and Tools Related Companies EPRX Competitors NKTX Competitors MGNX Competitors ASMB Competitors GLSI Competitors HURA Competitors THTX Competitors CTNM Competitors ATOS Competitors BHST Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VTL) was last updated on 6/14/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredGet in stocks now - and get out on this dateGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | Sponsored[First Look] Get in before potential 10X AI announcementsGo for 10X gains from the next big AI announcement — starting as soon as 7 days from now Former floor trade...Masters in Trading | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vital Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vital Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VTL Stock Free VTL Stock Alerts